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Introduction
Genitourinary health and sexual well-being
are critical aspects of quality of life and
overall health, especially for patients with
malignancy who face the negative physical
and emotional consequences of cancer and
cancer treatment. However, evidence suggests
that physicians rarely address these concerns
in clinical practice. As cancer survivorship
continues to improve with advancements in
detection and treatment, the need for
supportive gynecologic and sexual health care
for women with cancer is greater than ever.
The purpose of this study was to characterize
the prevalence of oncologist-reported
counseling for genitourinary syndromes
(GUS) or sexual health concerns (SHC) in
women with cancer being cared for at an
urban academic safety net hospital and to
identify potential gaps in care for this patient
population.

Tables and Figures

Figure 1: Model of sexual
health for cancer survivors.
Source: Seminars in Oncology
Nursing, vol. 36, Falk SJ, Dizon
DS., Sexual Health Issues in
Cancer Survivors.

Table 1: Genitourinary syndrome (GUS) and sexual health
concern (SHC) evaluation by cancer status.

Methods
A retrospective study of 514 women receiving
cancer treatment or follow-up cancer care
from January 24, 2022, to March 31, 2022,
was performed. Inclusion criteria consisted of
female patients aged 18 or older with a prior
or current cancer diagnosis. Demographics
and clinical data were abstracted from patient
charts to investigate factors associated with
screening for GUS or SHC. Charts were
further reviewed to determine whether the
oncologist initiated a treatment or referral
process for patients endorsing GUS or SHC.
Statistical analyses were conducted using R
statistical software version 4.0.2.
Demographic variables were compared
between groups using Wilcoxon rank sum
tests for continuous variables and Fisher exact
tests for categorical variables.

Results
A total of 68 of 514 (13.2%) subjects were asked
about GUS or SHC by their oncologist. Of the
patients that had these discussions, 25 (36.8%)
endorsed GUS or SHC. The majority (96.0%) of
patients who reported GUS or SHC received
treatment or referral for further care. Roughly onethird of gynecologic cancer survivors (37.2% of
cervical cancer, 31.3% of ovarian cancer, 36.8% of
vulvar cancer, and 30.2% of uterine cancer)
discussed GUS or SHC with their oncologist. In
contrast, only 7.2% of breast, 5.1% of colorectal, and
4.5% of other cancer survivors had documented
discussions of GUS or SHC. Documented
conversations about these topics were more common
in patients without evidence of disease (21.8% vs.
5.8%, p < .001). Patients who were not on active
treatment were more likely to have documented
discussions than those on active treatment (19.0% vs.
7.9%, p < .001). Patients on targeted therapy were
significantly less likely to have documented GUS or
SHC conversations with their oncologist (35.7% vs.
13.2%, p < .001). There were no other significant
differences by treatment type, race, ethnicity, need
for translator, insurance status, or BMI with regards
to counseling for GUS or SHC.

Conclusions
Figure 2: Follow up care by symptom category.

Women with gynecologic cancers were more likely
to have documented GUS or SHC counseling by
their oncologist than women with other cancers.
Patients without evidence of disease and not
receiving treatment were also more likely to have
documented discussions surrounding these issues.
Although only 13.2% of patients had documented
GUS or SHC conversations, most of those patients
were able to achieve follow-up care, illustrating a
large gap in care and revealing an opportunity to
address a significant quality of life issue for these
patients.

